Clinical Trials Browser

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Recurrence, Endometrial Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Small Cell Lung Carcinoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Low Grade Serous Ovarian Carcinoma

Breast Neoplasms

Breast Neoplasms, Male

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Liver Metastases From Colorectal Cancer (mCRC)

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Anatomic Stage IV Breast Cancer AJCC v8

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Adenocarcinoma of Endometrium

Breast Neoplasms

Breast Neoplasms

Malignant Neoplasms of Female Genital Organs

Breast Neoplasms, Neoplasm, Residual

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Endometrial Neoplasms

ER-Positive Breast Cancer

Neoplasm Metastasis

Breast Neoplasms

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Breast Neoplasms

Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Glioblastoma

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms

Brain Neoplasms, Glioblastoma

Glioblastoma

Advanced Breast Cancer

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

Breast Neoplasms

Astrocytoma, Brain Neoplasms, Ependymoma, Meningioma, Oligodendroglioma

Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

ABBY

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

EVOLVE-BDT

TAPUR

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

I-SPY

ALEPRO

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

ETHAN - ET for Male BC

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

FAIM

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

ABBICAR

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Abemaciclib in Newly Diagnosed Meningioma Patients

CARABELA

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

MiRaDoR

VIOLET

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Abemaciclib With or Without Atezolizumab for mCRPC

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

ALPINE: Maintenance Letrozole/Abemaciclib

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

GERTRUDE

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ARCHE

ABIGAIL

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

A Study of Abemaciclib in Recurrent Glioblastoma

Abemaciclib + Pembrolizumab In Glioblastoma

HERMIONE-7

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer